Cargando…
Dupilumab as a treatment for cutaneous immune-related adverse events induced by immune checkpoint inhibitors: A case series and review of the literature
Immune checkpoint inhibitors have revolutionized cancer treatment. They can induce cutaneous immune-related adverse events. One patient with immune-related eczema and two with immune-related bullous pemphigoid were successfully treated with dupilumab. Guidelines recommend the use of systemic steroid...
Autores principales: | Fournier, Cynthia, Hirsch, Ian, Spreafico, Anna, Butler, Marcus Otho, Dhani, Neesha, Sauder, Maxwell Benjamin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10467211/ https://www.ncbi.nlm.nih.gov/pubmed/37654554 http://dx.doi.org/10.1177/2050313X231195462 |
Ejemplares similares
-
The use of interleukin-23 inhibitors to treat immune-related psoriasis induced by immune checkpoint inhibitors and in patients with active cancer: A case series and review of the literature
por: Fournier, Cynthia, et al.
Publicado: (2023) -
Reader Comment Regarding “Cutaneous Immune-Related Adverse Events (irAEs) to
Immune Checkpoint Inhibitors: A Dermatology Perspective on Management”
por: Sauder, Maxwell, et al.
Publicado: (2021) -
Management of immune-related cutaneous adverse events with dupilumab
por: Kuo, Alyce Mei-Shiuan, et al.
Publicado: (2023) -
Kaposi sarcoma in a patient treated with upadacitinib for rheumatoid arthritis
por: Fournier, Cynthia, et al.
Publicado: (2023) -
Cutaneous sarcoidosis in a melanoma scar: A case report
por: Fournier, Cynthia, et al.
Publicado: (2019)